ANTX · AN2 Therapeutics Inc
United States · RS rating 45 · As of 2026-10-14
| Price | 3.54 USD |
|---|---|
| 1-day change | -1.7% |
| RS rating (overall / 1M / 3M / 12M) | 45 / 5 / 15 / 97 |
| Stage | Basing |
| Composite / Minervini / CANSLIM score | 29 / 35 / 26 |
| Industry group (rank) | Medical-Biomed/Biotech (167) |
| EPS growth Q/Q | +6.5% |
| Sales growth Q/Q | – |
| Distance from 52-week high | +43.6% |
| Market cap (USD) | $154.1M |